Found 44 cardiology trials
A listing of cardiology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
AIM HIGHer Clinical Trial
This is a multicenter, randomized, quadruple-blind, sham controlled, 2-part, embedded IDE clinical trial. The main objective is to evaluate the efficacy and safety of Cardiac Contractility Modulation (CCM) therapy in patients with symptomatic HF with LVEF 40-60%. The study is divided into 3 phases, screening, randomization (where 2/3 will be …
INTEGRA-D study
The INTEGRA D study will evaluate the safety and efficacy of the CCM D System in patients with heart failure symptoms despite being on GDMT and have an LVEF 40%.The This is designed as a single arm, prospective, multicenter study of 300 subjects that will establish that the device can …
Attralus AT02-001
To evaluate the safety and tolerability of IV AT-02 in subjects with systemic amyloidosis. To evaluate the clinical activity of AT-02. Cardiac MRI, NYHA functional classification,and echocardiogram. KCCQ-23, 6MWT
AT-02-003 Open-label Extension Study
To assess the long-term safety and tolerability of AT-02 in subjects with Systemic Amyloidosis. Incidence, frequency, and severity of treatment-emergent adverse events (TEAEs) and severity of treatment-emergent serious adverse events (TESAEs) Change from baseline in clinical laboratory values, electrocardiograms (ECGs), physical examinations, and vital signs Change from baseline in biomarkers …
ION-682884-CS12
This is a multicenter, eplontersen open-label extension of the ION-682884-CS2 Study and of the ISIS 420915-CS101 Study. Eligible subjects will receive 45 mg of eplontersen subcutaneously once every month for up to 36 months OR 6 months after eplontersen is health authorityapproved and available in the sites country, whichever occurs …
ALXN2220-ATTR-CM-301
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of amyloid depleter ALXN2220 compared to placebo in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).Approximately 1000 participants will be enrolled and randomized to receive either ALXN2220 or placebo in a 2:1 ratio. Participants will receive …
OPTION study
This study is a prospective, randomized, multi-center, global investigation to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation in patients after Atrial Fibrillation ablation.
Intellia NTLA-2001
To evaluate the efficacy of NTLA-2001, as measured by the composite risk of CV-related mortality and CV events (urgent HF visits and hospitalizations due to HF, MI, arrhythmia, or stroke), compared to placebo Composite endpoint comprising Cardiovascular related mortality and frequency and timing of Cardiovascular events (urgent Heart Failure visits …
BACKBEAT
This is a prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel AV interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic pacemaker. Patients within 90 days of de novo implant of an Astra/Azure pacemaker also having uncontrolled hypertension may be approached for …
CentriMag Failure-to-Wean Post cardiopulmonary bypass
This study will gather real-world information on the post-market performance, and confirm safety and effectiveness of the CentriMag Circulatory Support System for patients surviving up 30 days post support or to hospital discharge, and for subjects who do not recover and are bridged to a heart transplant or long-term assist …
